148 related articles for article (PubMed ID: 19236136)
21. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
[TBL] [Abstract][Full Text] [Related]
22. Health economics of use fluoroquinolones to treat patients with community-acquired pneumonia.
Restrepo MI; Frei CR
Am J Med; 2010 Apr; 123(4 Suppl):S39-46. PubMed ID: 20350634
[TBL] [Abstract][Full Text] [Related]
23. Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia.
Clark LC; Davis CW
Am J Health Syst Pharm; 2000 Nov; 57 Suppl 3():S10-3. PubMed ID: 11098314
[TBL] [Abstract][Full Text] [Related]
24. Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms.
Neidell MJ; Cohen B; Furuya Y; Hill J; Jeon CY; Glied S; Larson EL
Clin Infect Dis; 2012 Sep; 55(6):807-15. PubMed ID: 22700828
[TBL] [Abstract][Full Text] [Related]
25. The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy.
Rhew DC; Hackner D; Henderson L; Ellrodt AG; Weingarten SR
Chest; 1998 Jan; 113(1):142-6. PubMed ID: 9440581
[TBL] [Abstract][Full Text] [Related]
26. Switch therapy in community-acquired pneumonia.
Ramirez JA
Diagn Microbiol Infect Dis; 1995; 22(1-2):219-23. PubMed ID: 7587043
[TBL] [Abstract][Full Text] [Related]
27. Community-acquired pneumonia team decreases length of stay in hospitalized, low-risk patients with pneumonia.
Marcos PJ; Restrepo MI; Sanjuàn P; Ferreira-Gonzalez L; Verea-Hernando H
Hosp Pract (1995); 2013 Aug; 41(3):7-14. PubMed ID: 23948616
[TBL] [Abstract][Full Text] [Related]
28. Clinical and economic outcomes in the treatment of lower respiratory tract infections.
Brixner DI
Am J Manag Care; 2004 Oct; 10(12 Suppl):S400-7. PubMed ID: 15603249
[No Abstract] [Full Text] [Related]
29. [The clinical and economic aspects of treating community-acquired pneumonias].
Tiurin VP; Dmitriev IuK; Duganov VK; Bogdanov MB
Voen Med Zh; 2000 Apr; 321(4):28-31. PubMed ID: 10860468
[No Abstract] [Full Text] [Related]
30. Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
Rapp RP
Postgrad Med; 2002 Sep; 112(3 Suppl):12-7. PubMed ID: 19667590
[TBL] [Abstract][Full Text] [Related]
31. Direct costs in patients hospitalised with community-acquired pneumonia after non-response to outpatient treatment with macrolide antibacterials in the US.
Paladino JA; Adelman MH; Schentag JJ; Iannini PB
Pharmacoeconomics; 2007; 25(8):677-83. PubMed ID: 17640109
[TBL] [Abstract][Full Text] [Related]
32. Application of antimicrobial stewardship to optimise management of community acquired pneumonia.
Bosso JA; Drew RH
Int J Clin Pract; 2011 Jul; 65(7):775-83. PubMed ID: 21676120
[TBL] [Abstract][Full Text] [Related]
33. Potential for cost-savings in the care of hospitalized low-risk community-acquired pneumonia patients in China.
Zhou QT; He B; Zhu H
Value Health; 2009; 12(1):40-6. PubMed ID: 18637052
[TBL] [Abstract][Full Text] [Related]
34. Appropriate outpatient macrolide use in community-acquired pneumonia.
Gotfried MH
J Am Acad Nurse Pract; 2004 Apr; 16(4):146, 148, 150 passim. PubMed ID: 15137473
[TBL] [Abstract][Full Text] [Related]
35. [Community-acquired pneumonia: influence of the duration of intravenous antibiotic therapy on hospital stay and the cost-benefit ratio].
Fernández Alvarez R; Gullón Blanco JA; Rubinos Cuadrado G; Jiménez Sosa A; Hernández García C; Medina Gonzálvez A; González Martín I
Arch Bronconeumol; 2001 Oct; 37(9):366-70. PubMed ID: 11674935
[TBL] [Abstract][Full Text] [Related]
36. Impact of superinfection on hospital length of stay and costs in patients with ventilator-associated pneumonia.
Eagye KJ; Nicolau DP; Kuti JL
Semin Respir Crit Care Med; 2009 Feb; 30(1):116-23. PubMed ID: 19199193
[TBL] [Abstract][Full Text] [Related]
37. Short-course antimicrobial therapy for community-acquired pneumonia.
Kolditz M; Halank M; Höffken G
Treat Respir Med; 2005; 4(4):231-9. PubMed ID: 16086597
[TBL] [Abstract][Full Text] [Related]
38. Strategies for early discharge of the hospitalized patient with community-acquired pneumonia.
Siegel RE
Clin Chest Med; 1999 Sep; 20(3):599-605. PubMed ID: 10516907
[TBL] [Abstract][Full Text] [Related]
39. A tailored implementation strategy to reduce the duration of intravenous antibiotic treatment in community-acquired pneumonia: a controlled before-and-after study.
Engel MF; Bruns AH; Hulscher ME; Gaillard CA; Sankatsing SU; Teding van Berkhout F; Emmelot-Vonk MH; Kuck EM; Steeghs MH; den Breeijen JH; Stellato RK; Hoepelman AI; Oosterheert JJ
Eur J Clin Microbiol Infect Dis; 2014 Nov; 33(11):1897-908. PubMed ID: 24859925
[TBL] [Abstract][Full Text] [Related]
40. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients.
McCollum M; Sorensen SV; Liu LZ
Clin Ther; 2007 Mar; 29(3):469-77. PubMed ID: 17577468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
